slc35e3 Antibody

What is SLC35E3 and what is its biological significance?

SLC35E3 (Solute Carrier Family 35, Member E3) is a member of the nucleoside sugar transporter subfamily E. This protein consists of 313 amino acids and is also known as BLOV1 in some research contexts . SLC35E3 plays a significant role in carbohydrate derivative transport as part of biological processes, particularly in the Golgi complex and/or endoplasmic reticulum . The protein is involved in glycol-conjugation processes, with defective function potentially leading to impaired glycosylation of proteins and lipids in these cellular compartments.

The importance of SLC35E3 extends beyond basic cellular functions, as recent research has implicated it in cardiovascular disease (CVD) pathology. Specifically, SLC35E3 has been identified as a target of novel microRNA m1061-5p, which may repress its expression in patients with cardiovascular disease . This connection suggests that altered SLC35E3 function may contribute to disease mechanisms, making it a protein of interest for researchers studying CVD and related conditions.

What detection techniques are validated for SLC35E3 in research applications?

Based on current research protocols, immunohistochemistry (IHC) is a well-established technique for detecting SLC35E3 in human tissues. The recommended dilution range for IHC applications is 1:20 to 1:50 when using validated antibodies . This technique allows researchers to visualize the spatial distribution of SLC35E3 across different tissue types and cellular compartments.

Beyond IHC, molecular detection of SLC35E3 has been successfully performed using RT-qPCR with specific primers. For instance, researchers have used primers targeting SLC35E3 (forward: 5′-ACGACAGGTGATCCACCTGC-3′, reverse: 5′-TATGAACCAACAAATACACC-3′) in combination with reference genes for expression analysis . Western blotting is another viable technique, with antibody specificity confirmed through Bis-Tris PAGE analysis showing a purity of >90% for commercial antibodies .

For researchers planning comprehensive characterization studies, it's worth noting that the Human Protein Atlas project has generated extensive data on SLC35E3 expression across numerous tissues through systematic antibody-based profiling, providing valuable reference information for experimental design and validation .

How does SLC35E3 expression correlate with cardiovascular disease development?

SLC35E3 has emerged as a potential marker in cardiovascular disease research through its identification as a target of novel-m1061-5p microRNA. Studies comparing blood samples from CVD patients with healthy controls have revealed that novel-m1061-5p may repress the expression of SLC35E3 in individuals with cardiovascular disease . This regulatory relationship is particularly significant because SLC35E3's involvement in carbohydrate derivative transport processes may impact glycosylation patterns that are critical for proper cardiovascular function.

The research methodology employed to establish this correlation involved deep sequencing of blood samples from three patients with CVD and three controls using the Illumina HiSeq 2000 system. The differential expression analysis revealed that novel-m1061-5p was upregulated in CVD patients, suggesting a potential mechanism where increased levels of this microRNA lead to decreased SLC35E3 expression . Further validation through RT-qPCR confirmed these findings, supporting the hypothesis that SLC35E3 dysregulation may contribute to cardiovascular pathophysiology.

What are the optimal methodological approaches for studying SLC35E3 expression across different human tissues?

To effectively study SLC35E3 expression patterns across human tissues, researchers should employ a multi-technique approach that encompasses both protein and transcript detection methods. For protein-level analysis, immunohistochemistry using specific antibodies at dilutions of 1:20-1:50 has proven effective . The Prestige Antibodies® approach, which involves testing on tissue arrays comprising 44 normal human tissues and 20 common cancer types, represents the gold standard for tissue-wide expression profiling.

For transcript-level analysis, RT-qPCR with validated primers targeting SLC35E3 provides quantitative expression data. When designing such experiments, researchers should normalize expression using appropriate reference genes such as U6, calculating relative expression using the 2^(-ΔΔCq) method as demonstrated in previous cardiovascular studies . The combination of protein and transcript detection provides a more comprehensive understanding of SLC35E3 expression regulation.

For researchers pursuing high-throughput screening approaches, it's worth noting that previous studies have successfully incorporated SLC35E3 expression analysis into broader transcriptomic datasets, as evidenced by the identification of 65 abnormal miRNAs (59 upregulated, 6 downregulated) that target 2,784 genes, including SLC35E3, in cardiovascular disease patients . This methodology can be adapted to investigate SLC35E3 expression patterns in other disease contexts or physiological conditions.

What validation steps should be taken to ensure SLC35E3 antibody specificity?

Ensuring antibody specificity is critical for generating reliable research results. For SLC35E3 antibodies, validation should follow a multi-step process. First, researchers should verify that the antibody recognizes the correct immunogen sequence. The established SLC35E3 antibody targets the sequence QNNTIGTYQLAKAMTTPVIIAIQTFCYQK, which corresponds to a specific region of the protein . Validation experiments should confirm binding to this sequence.

Second, cross-reactivity testing against similar proteins should be performed. High-quality SLC35E3 antibodies are typically tested against protein arrays containing hundreds of human recombinant protein fragments. For example, established antibodies have been validated against arrays of 364 human recombinant protein fragments to ensure minimal cross-reactivity . This extensive testing provides confidence in the specificity of the antibody for SLC35E3.

Finally, researchers should include appropriate positive and negative controls in their experiments. Positive controls may include tissues known to express SLC35E3, while negative controls might involve tissues where SLC35E3 expression is absent or tissues from knockout models if available. Additionally, using competing peptides that block antibody binding can provide further evidence of specificity. Documenting these validation steps is essential for publication-quality research involving SLC35E3 antibodies.

What are the optimal protocols for immunohistochemical detection of SLC35E3?

For optimal immunohistochemical detection of SLC35E3, researchers should follow a structured protocol based on validated methods. Begin with proper tissue fixation, typically using formalin, followed by paraffin embedding. Section preparation should be standardized, with 4-6 μm sections mounted on positively charged slides. Antigen retrieval is a critical step, with heat-induced epitope retrieval in citrate buffer (pH 6.0) recommended for most applications involving SLC35E3 antibodies.

For primary antibody incubation, the recommended dilution range for anti-SLC35E3 antibodies is 1:20 to 1:50 . Incubation should occur overnight at 4°C in a humidified chamber to ensure optimal antibody binding with minimal background. Following primary antibody incubation, use an appropriate detection system compatible with rabbit-derived antibodies, as commercial SLC35E3 antibodies are typically raised in rabbits .

For visualization, DAB (3,3'-diaminobenzidine) provides a stable chromogen that allows for detailed analysis of SLC35E3 expression patterns. Counterstaining with hematoxylin provides cellular context without interfering with the primary signal. Quality control should include both positive and negative controls in each staining run, and all staining results should be quantified using standardized scoring systems to ensure reproducibility across experiments.

How can researchers overcome common challenges in SLC35E3 detection?

Researchers working with SLC35E3 antibodies may encounter several challenges, including non-specific binding, variable staining intensity, and inconsistent results between experiments. To address non-specific binding, implement more stringent blocking procedures using 5% normal serum from the same species as the secondary antibody, combined with 1% BSA in PBS for at least 1 hour at room temperature. Additionally, increasing the washing steps (at least three 5-minute washes with PBS-T) between antibody incubations can significantly reduce background.

For variable staining intensity, standardize tissue processing and handling procedures across all samples. Freshly prepared antibody dilutions should be used for each experiment, and antibody solutions should be properly stored according to manufacturer recommendations (typically at -20°C for glycerol-containing solutions like anti-SLC35E3 antibodies) . When working with tissues known to have low SLC35E3 expression, signal amplification systems may be employed, though these should be carefully validated to ensure they don't introduce artifacts.

To address batch-to-batch variation, researchers should consider running standardization samples across different experimental batches and normalizing results accordingly. Documentation of all experimental parameters, including antibody lot numbers, incubation times, and temperatures, is essential for troubleshooting and ensuring reproducibility. For particularly challenging applications, optimizing the detection system (such as switching from conventional immunohistochemistry to more sensitive methods like tyramide signal amplification) may improve results.

What are the emerging applications of SLC35E3 antibodies in cardiovascular research?

Emerging applications of SLC35E3 antibodies in cardiovascular research center on their potential use as diagnostic and prognostic tools. The identification of SLC35E3 as a target of novel-m1061-5p microRNA, which is upregulated in cardiovascular disease, suggests that SLC35E3 protein expression levels may serve as a molecular marker for disease progression . Researchers are beginning to explore the utility of SLC35E3 immunostaining in tissue samples from patients with various cardiovascular pathologies to establish expression patterns that correlate with disease severity.

Another promising application involves the use of SLC35E3 antibodies in mechanistic studies examining the relationship between altered glycosylation patterns and cardiovascular dysfunction. As a member of the nucleoside sugar transporter family involved in carbohydrate derivative transport, SLC35E3 may play a crucial role in glycosylation processes that affect cardiovascular biology . Co-localization studies using SLC35E3 antibodies alongside markers of protein glycosylation could provide insights into the molecular basis of cardiovascular disease.

Additionally, the development of multiplexed immunofluorescence protocols incorporating SLC35E3 antibodies allows researchers to simultaneously examine multiple proteins within the same tissue section. This approach facilitates the investigation of potential interaction networks involving SLC35E3 in cardiovascular tissues. As research in this area advances, SLC35E3 antibodies may become valuable tools for identifying patient subgroups likely to benefit from targeted therapeutic interventions aimed at modulating glycosylation processes in cardiovascular disease.

How should researchers interpret SLC35E3 expression data in the context of microRNA regulation?

Interpreting SLC35E3 expression data in the context of microRNA regulation requires an integrated analysis approach combining multiple data types. When examining the relationship between novel-m1061-5p and SLC35E3, researchers should first establish baseline expression levels of both molecules in relevant tissues or cell types using RT-qPCR with appropriate normalization controls, such as U6 for microRNAs . Correlation analysis between miRNA levels and SLC35E3 expression can then reveal potential regulatory relationships.

For robust data interpretation, researchers should consider several analytical approaches. First, the fold change calculation using the 2^(-ΔΔCq) method provides a standardized way to compare expression between different conditions (such as disease vs. control) . Second, statistical testing with appropriate corrections for multiple comparisons (such as q-value adjusted p-values) ensures that observed differences are statistically significant. In previous cardiovascular studies, a threshold of log2(fold change) > 1 and p < 0.05 was used to identify differentially expressed miRNAs .

Additionally, computational target prediction tools like miRanda can be employed to validate the interaction between novel-m1061-5p and SLC35E3. When interpreting such predictions, researchers should look for perfect matches in the cleavage site (typically the 10th to 11th nucleotides) and limit mismatches to fewer than five . Functional validation through luciferase reporter assays or similar techniques provides the strongest evidence for direct miRNA-target interactions. By integrating these multiple layers of evidence, researchers can build a comprehensive understanding of how microRNA regulation affects SLC35E3 expression in normal and disease states.

What bioinformatic approaches can help predict SLC35E3 function in different cellular contexts?

Bioinformatic analysis of SLC35E3 can provide valuable insights into its potential functions across different cellular contexts. Gene Ontology (GO) analysis has already linked SLC35E3 to carbohydrate derivative transport biological processes , serving as a starting point for functional predictions. Researchers can expand on this by conducting protein domain analysis to identify functional motifs within the 313 amino acid sequence of SLC35E3 that might suggest specific molecular mechanisms.

Pathway enrichment analysis, such as KEGG pathway mapping, can place SLC35E3 within broader biological systems. Previous research has shown that genes targeted by miRNAs in cardiovascular disease are enriched in pathways related to lipid and glycan metabolism . Researchers can leverage this information to generate hypotheses about SLC35E3's role in these pathways, particularly in cardiovascular contexts.

Comparative analysis across species can also provide evolutionary insights into SLC35E3 function. Conserved sequences across species often indicate functionally important domains. Additionally, researchers should employ protein-protein interaction prediction tools to identify potential binding partners of SLC35E3, generating hypotheses about its participation in molecular complexes. Network analysis integrating expression data across multiple tissues from resources like the Human Protein Atlas can further reveal tissue-specific functions of SLC35E3. These bioinformatic approaches, when combined with experimental validation using SLC35E3 antibodies, can significantly advance our understanding of this protein's biological roles.